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Conclusion: Severe reductions in target dose coverage were 
observed as an effect of interfractional anatomical changes. 
The difference between the position verification methods 
was a lesser issue compared to the effect of the anatomical 
changes. 
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Purpose or Objective: The new ESTRO consensus guideline 
for target delineation for elective breast radiotherapy 
(Offersen Radiother Oncol. 2015) establish the humeral head 
and connective tissues 10 mm around it as Planning Risk 
Volume (PRV). The objective was to implement these 
guidelines for sparing the humeral head in elective breast 
radiotherapy with level 1 and 2 (L1/L2) lymph nodes by 
comparing three different planning techniques. 
 
Material and Methods: Ten patients with left-sided breast 
cancer were enrolled in a planning study performed in 
Pinnacle3 v9.8 (Philips). All patients were planned with 16 x 
2.66Gy on the breast (PTVp) and the elective L1/L2 lymph 
nodes (PTVn). We compared three techniques: IMRT with high 
tangential field (HTF), 6-field IMRT and VMAT. The humeral 
head PRV (hh+10) was included with an objective of V40Gy < 
1cc for all three techniques. Treatment plans were obtained 
with the inverse planning tool and optimization was achieved 
by decreasing the dose to the organs at risk (OARs; lungs, 
heart and right breast) as low as possible while maintaining a 
PTVp V95% of 97% and PTVn V90% of 95%.  
For the high tangential fields, the cranial border of the fields 
was extended to include PTVn. The leaves of the 5 mm multi 
leaf collimator were then closed to exclude hh+10 to reduce 
the dose to the humeral head and the surrounding tissue. 
This technique is currently used in our clinic. The 6-field 
IMRT technique consisted of tangential fields and four 
additional fields (at 330, 20, 80 and 170 degrees) to ensure 
proper coverage of the cranial part of the breast and the 
lymph nodes. The cranial border of the tangential fields and 
caudal border of the four additional fields was set 1cm below 
the attachment of the clavicle at the sternum. The third 
technique was a VMAT dualarc from 305 to 180 degrees.  
 
Results: HTF resulted in an average PTVp V95% of 97.2% and 
an average PTVn V90% of 90.4% (see Table 1). With the 
additional fields of the 6-field IMRT technique, the coverage 
of the lymph nodes increased significantly to on average 
98.0% (p = 0.01) while PTVp did not vary significantly (p = 
0.92). The doses to the OAR were comparable between the 
HTF and IMRT technique. The coverage of PTVn increased 
when using VMAT to an average of 99.5% (p < 0.01 compared 
to HTF and p = 0.19 compared to IMRT). The dose to the OAR 
increased as well. The mean dose to the contralateral breast 
increased significantly from 0.6Gy with HTF and IMRT to 
2.3Gy with VMAT (p < 0.01 for both). 
 
 
 
Conclusion: The humeral head and surrounding tissues as 
defined in the new ESTRO guideline can be spared with the 6-
field IMRT or VMAT technique. It is not possible through high 
tangential fields without reducing PTVn coverage.  
A 6-field IMRT technique including tangential fields and four 
additional fields to cover the lymph nodes and the cranial 
part of the breast leads to adequate coverage of the primary 
target and the lymph nodes without increasing the dose to 
the other OARs. 
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Purpose or Objective: Stereotactic radiotherapy near critical 
serial organs at risk (OAR) requires specific caution to avoid 
severe toxicity. Current strategies are to (1) to rule out SBRT 
as a treatment option, (2) to use full dose SBRT and expose 
patients to higher risks, (3) to homogenously underdose the 
entire planning target volume (PTV), or (4) to trim PTV 
margins individually and non-quantifiably. We here describe a 
novel IMRT prescription method termed simultaneous 
integrated protection (SIP) for quantifiable and comparable 
dose prescription to targets very close to dose limiting 
structures. This work will be focussed on the planning of 
SBRT. 
 
Material and Methods: For patients with infringement of 
dose constraints to at least one serial OAR, e.g. central 
airways, bowel, we defined a planning risk volume (PRV). The 
intersection volume of the PRV with the total planning target 
volume (PTV_Σ) was defined as the protection PTV_SIP and 
the vast non-intersecting majority of PTV_Σ as the dominant 
PTV (PTV_dom). Radiotherapy treatment planning was 
performed using IMRT. Dose was prescribed to PTV_dom 
according to ICRU in 3, 5, 8 or 12 fractions. If in doubt, 
preference to a higher number of fractions was given as a 
function of the size of PTV_SIP. D_max was allowed to be up 
to 130% of the prescribed dose. No specific dose was 
prescribed to the PTV_SIP but dose was required to stay just 
within the constraints for the respective OAR. Dose-volume-
histogram (DVH) analysis was based on absolute volumes of 
OARs, not on PRVs. 
 
Results: This method led to a fall off region within PTV_SIP 
between the PTV_dom and the OAR. We here demonstrate 
this approach for six patients. Two had lesions in the chest, 
one in the liver, two in the pancreas and one in the left 
kidney (Figure 1). Size of the PTVs (PTV_Σ) ranged from 14.5 
to 84.9 mL (median 49.2 mL, mean 49.7 mL; Figure 2). Sizes 
of PTV protection subvolumes (PTV_SIP) ranged from 1.8 – 3.9 
mL (median and mean 2.8 mL). Relative PTV_SIP ranged from 
2.9% - 13.4% of the size of PTV_Σ (median 7.4%). Noteworthy, 
the largest ratio, 13.4%, was an absolute volume of 2 mL, 
only. D_min of the PTV_SIP was significantly lower in patients 
